 |
|
|
| |
Pharmacokinetic Interaction Of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy Subjects
|
| |
| |
Reported by Jules Levin
Presented at HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis, December 8-12, 2013, Big Island, Hawaii
WW Yeh1, IP Fraser1, C Reitmann1, L Caro1, A Mitselos2, J-F Denef2, I De Lepeleire2, JN de Hoon3, C Vandermeulen3, JA Wagner1, JR Butterton1
1Merck & Co., Inc., Whitehouse Station, NJ, 2Merck, Sharp & Dohme, Brussels, Belgium, 3Universitair Ziekenhuis Leuven, Campus Gathuisberg, Center for Clinical Pharmacology, Leuven, Belgium
|
| |
|
|
|
|
|
